HIV-1 Vaccine Shows Strong T-Cell Response in Phase 1 Study
The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad T-cell responses makes it a promising tool for HIV-1 prevention and cure strategies.
METHODOLOGY:
HIVconsvX is an experimental vaccine comprising six cross-clade conserved HIV immunogens, delivered in two stages using nonreplicating vectors — initially a chimpanzee adenovirus (ChAdOx1), followed by a modified vaccinia virus Ankara (MVA).
Researchers conducted a phase 1 randomized clinical trial across clinical research centers in Uganda, Kenya, and Zambia to evaluate the safety and immunogenicity of the HIVconsvX T-cell vaccine, delivered in a regimen that included ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), and MVA.tHIVconsv4 (M4).
Overall, 88 healthy adults without HIV-1 (median age, 30 years; 65% men) were randomly assigned to receive either the vaccine (n = 72) or placebo (n = 16) from July 2021 to November 2022 and were followed up for 40 weeks.
Participants in the vaccine group received a C1 prime dose on day 0, followed by M3 and M4 boosters on day 28; participants in the placebo group received placebo doses on days 0 and 28.
The primary endpoint was vaccine safety, with solicited and unsolicited adverse events, including serious events, assessed until the end of the study period and measurement of HIVconsvX-specific T-cell responses.
TAKEAWAY:
Overall, the vaccine regimen was well tolerated with no grade 3 solicited reactions after the C1 administration; 18% were grade 2, and only 2% were grade 3 after M3/M4.
The vaccine regimen was highly immunogenic, inducing HIVconsvX-specific responses in 99% of participants who completed all vaccine doses ( P < .0001).
< .0001). HIVconsvX-specific T cells peaked at a median of 2310 spots per million peripheral blood mononuclear cells. Men had significantly higher responses than women ( P = .0451).
= .0451). Upon reexposure to the virus, the T cells proliferated and neutralized HIV-1 isolates from clades A, B, C, and D.
IN PRACTICE:
'We foresee the future development and use of the HIVconsvX vaccines as a potentially key component of a combined package of tools for cure and prevention,' the authors wrote.
SOURCE:
This study was led by Chama Chanda, MB ChB, Center for Family Health Research Zambia, Lusaka, Zambia. It was published online on May 16, 2025, in The Lancet Microbe .
LIMITATIONS:
This study looked at responses in peripheral blood mononuclear cells, whereas control of HIV-1 is primarily mediated in lymphoid organs and tissues, such as the gut.
DISCLOSURES:
This study was funded by the European and Developing Countries Clinical Trials Partnership. One author was a co-inventor of the HIVconsvX immunogens. Other authors declared having no competing interests.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Researchers make key breakthrough in fight against growing crisis that threatens entire planet: 'No community is unaffected'
Communities are important when it comes to tackling the world's growing plastic problem, according to a group of researchers. In their paper, published in the journal Microplastics and Nanoplastics, the scientists argued for a radical shift that sees communities as equal partners in co-creating research, knowledge, and action. The paper, summed up by the University of Portsmouth, was developed through an interdisciplinary workshop at the National Oceanography Centre in the United Kingdom. The team highlighted the diverse ways that communities communicate about plastic pollution, including through puppet shows, participatory art, citizen science, and indigenous knowledge. For example, researchers from the University of Portsmouth worked with waste pickers in Kenya to create a piece of "legislative theater" that explored issues such as policymaking, discrimination, and job insecurity. "In many contexts, especially in under-resourced areas, lack of formal education does not mean lack of knowledge," said study author Lesley Henderson of the University of Strathclyde. "Scientists must be careful not to conflate the two." Meeting the plastics crisis head-on has become increasingly important. As the University of Portsmouth summary pointed out, estimates suggest that by 2040, up to 29 million tons of plastic could enter oceans each year, which is more than double the 2010 numbers. As these plastics degrade over time, they break into smaller microplastics and nanoplastics, which further threaten the environment and human health. While researchers are still exploring all of the health impacts of microplastic exposure, these tiny particles have been tied to problems such as cancer, dementia, and impaired blood flow in the brain. Meanwhile, scientists are exploring new methods to clean up plastics from the environment. For instance, one team discovered that egg whites can filter microplastics out of ocean water. Another group found a way to remove microplastics from the soil using a type of processed farm waste. Individuals can help with the problem by reducing the amount of plastic they use. Reach for reusable shopping bags and water bottles, for instance, and opt for bar soap instead of the bottled varieties. "Given the ubiquity of plastics in our day-to-day lives, and subsequently as an environmental pollutant, no community is unaffected by this issue," the paper stated. Lead author Alice Horton of the National Oceanography Centre added: "Communities are not 'out there' waiting to be engaged. They are dynamic, diverse, and already playing critical roles in shaping how we understand and respond to ocean plastics." Do you think America has a plastic waste problem? Definitely Only in some areas Not really I'm not sure Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
3 days ago
- Yahoo
BMO says lenacapavir approval for prevention a ‘major win' for Gilead
Although largely as expected by investors, BMO Capital says lenacapavir's approval for prevention, now known as Yeztugo, marks 'a major win for Gilead (GILD)' in driving meaningful growth in its pre-exposure prophylaxis business. A clean label, strong clinical data, and a convenient twice yearly dosing regimen, in line with patient physician visits, should drive strong commercial adoption for Yeztugo, says the analyst, who has an Outperform rating and $120 price target on Gilead shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue Cautious Optimism for Gilead Sciences Amid Yeztugo's Market Challenges Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead Mizuho says Gilead Yeztugo label looks clean Gilead Sciences' Yeztugo Approval and Market Expansion Drive Buy Rating Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option
Medscape
3 days ago
- Medscape
HIV Prevention Vaginal Ring Recommended for 16-Year-Olds
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an extension of indication for dapivirine vaginal ring 25 mg to include its use in women from 16 years of age. The EMA said there had been some uncertainties about the risk for resistance and the benefits in younger women, which needed to be addressed. Upon further study, the ring was shown to be moderately effective at lowering the risk for HIV-1 infection following vaginal intercourse, with its side effects considered manageable. As such, the EMA decided that its benefits outweigh the risks in women who are not using oral pre-exposure prophylaxis (PrEP). The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older through vaginal intercourse, when taking PrEP medicines by mouth was not feasible. It is the first long-acting technology approved for HIV prevention in women and is intended for use outside the EU. The device was submitted under a regulatory procedure, EU- Medicines for all (EU-M4All) that enables the EMA, in collaboration with the World Health Organization (WHO), to provide scientific opinions on high priority human medicines that are intended for markets outside the EU. The process allows the European agency to support global regulatory capacity building and contributes to the protection and promotion of public health beyond the EU. Its overall aim is to facilitate access to essential medicines in low- and middle-income countries that are intended to prevent or treat diseases of major public health interest. The flexible silicone ring is inserted in the vagina for a period of 28 days, after which it should be replaced by a new one. It works by slowly releasing dapivirine over the course of a month, which blocks the ability of HIV to make copies of itself inside healthy cells. It can be inserted and removed by the user. A study conducted in almost 2000 women in sub-Saharan Africa showed that dapirivine vaginal ring 25 mg lowered the chances of being infected with HIV by more than one third over the course of 24 months compared with the placebo group. It was first developed by the International Partnership for Microbicides and since acquired by the Population Council in 2022. It was first approved in 2021 by the Medicines Control Authority of Zimbabwe and has since been approved in several additional African countries. The ring has been on the WHO's prequalification list of medicines since November 2020 following positive scientific opinion from the EMA. The WHO has said it is intended to reduce the risk of acquiring HIV during vaginal sex for women who are at substantial HIV risk as a complementary prevention approach in addition to other safer-sex practices. The CHMP's opinion to extend the indication for this medicine to include its use in women from 16 years of age expands the HIV prevention choice beyond condoms and oral PrEP and could be an important tool to protect younger women from becoming HIV-positive.
